Highlights
- Third quarter 2026 license and collaboration Revenue was $274.4 million, compared with $4.7 million, and Net Income was $220.0 million.
- Diluted net income per share was $3.07 for the quarter, compared with a net loss per share of $0.62.
- The board authorized a share repurchase program of up to $300.0 million of common stock on September 8, 2026.
- FDA approval of MIMRYLO in August 2026 triggered a $200.0 million opt-out payment and a separate $75.0 million milestone payment.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shares were trading at USD 122.52 on November 20, 2026, down 1.21%, with a relative Volume at time of 1.93. The biopharmaceutical company announced a $300.0 million share repurchase program on September 8, 2026, and filed its Quarterly Report for the period ended September 30, 2026 on November 6, 2026.
Protagonist Therapeutics is a Delaware corporation with principal executive offices in Newark, California. It is a biopharmaceutical company built on a proprietary peptide technology platform. Its programs fall into three broad therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. It has license and collaboration agreements with Johnson & Johnson for oral IL-23R antagonist candidates, including ICOTYDE, and with Takeda for MIMRYLO.
Share Repurchase Program and Third Quarter Results
On September 8, 2026, the company announced that its Board of Directors authorized a share repurchase program under which it may repurchase up to $300.0 million of its outstanding common stock. The program has no fixed expiration, does not obligate the company to repurchase any specific number of shares and may be modified, suspended or discontinued at any time.
For the three months ended September 30, 2026, license and collaboration revenue was $274.4 million, compared with $4.7 million a year earlier. Research and Development expense was $41.3 million, compared with $40.0 million, and general and administrative expense was $13.7 million, compared with $11.1 million.
Income from operations was $218.3 million, compared with a loss from operations of $46.4 million. Income tax expense was $6.6 million. Net income was $220.0 million, compared with a net loss of $39.3 million. Basic net income per share was $3.32 and diluted net income per share was $3.07, compared with a net loss per share of $0.62.
Nine-Month Results
For the nine months ended September 30, 2026, license and collaboration revenue was $544.3 million, compared with $38.6 million. Income from operations was $373.5 million, compared with a loss from operations of $107.8 million.
Net income was $386.6 million, compared with a net loss of $85.8 million. Basic net income per share was $5.88 and diluted net income per share was $5.43, compared with a net loss per share of $1.35.
Collaboration Agreements
Under the JNJ License and Collaboration Agreement, the company earned a $50.0 million milestone payment in the first quarter of 2026 upon FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis. It has earned a total of $387.5 million in upfront and milestone payments from JNJ from inception in 2017 through September 30, 2026, and is eligible for tiered royalties of 6% to 10% on net product sales and sales milestones of up to $425.0 million.
Under the Takeda Collaboration Agreement, the company announced on April 28, 2026 that it exercised its right to opt out of the U.S. profit and loss sharing arrangement. The opt-out triggered a $200.0 million payment, and the FDA's approval of MIMRYLO in August 2026 triggered an additional $200.0 million opt-out payment and a separate $75.0 million milestone payment. The company is eligible to receive up to $800.0 million in development and sales milestone payments for MIMRYLO in polycythemia vera, and tiered royalties of 14% to 29% on annual net worldwide sales. It said the MIMRYLO open-label extension is expected to be completed in the first quarter of 2027.
Balance Sheet
Cash and cash equivalents were $498.3 million at September 30, 2026, compared with $128.4 million at December 31, 2025. Current marketable securities were $301.8 million, compared with $439.0 million. Total Assets were $1.15 billion, compared with $668.2 million, total liabilities were $61.6 million, and total stockholders' Equity was $1.08 billion, compared with $614.7 million.






Please wait processing your request...